This is a routine investor presentation update with no new financial data or guidance. The key catalyst to watch is the Q4 2026 BLA submission for aglatimagene in prostate cancer. Monitor for any regulatory updates or partnership announcements that could validate the commercial opportunity.
Price Chart
Executive Summary
Candel Therapeutics filed an 8-K furnishing a September 2026 corporate investor presentation. The presentation highlights positive Phase 3 data for aglatimagene in prostate cancer (30% risk reduction in disease recurrence, HR=0.70), encouraging Phase 2a NSCLC data (mOS 25.4 months), and progress with linoserpaturev in recurrent high-grade glioma. The company expects a BLA submission for aglatimagene in Q4 2026 and has cash of $201.6M providing runway into Q1 2028, but the filing is a routine investor update with no new material financial disclosures or guidance changes.
Key Facts
- Phase 3 trial of aglatimagene in prostate cancer achieved primary endpoint: 30% risk reduction in DFS (HR=0.70, P=0.0155).
- Phase 2a NSCLC data showed mOS of 25.4 months in per-protocol population vs historical SOC chemo of 9.8-11.8 months.
- BLA submission for aglatimagene in prostate cancer expected in Q4 2026.
- Cash and cash equivalents of $201.6 million as of June 30, 2026; expected runway into Q1 2028.
- Entered into a $100 million royalty funding agreement with RTW Investments in February 2026, subject to FDA approval of aglatimagene.
- Entered into a term loan facility with Trinity Capital of up to $130 million in October 2025.
Financial Impact
Cash and cash equivalents of $201.6 million as of June 30, 2026; no revenue or earnings reported in this filing.
Risk Factors
- Regulatory risk: BLA submission and FDA approval for aglatimagene are not guaranteed.
- Clinical risk: Phase 3 NSCLC trial and linoserpaturev trials are ongoing with uncertain outcomes.
- Commercial risk: Market adoption and reimbursement for aglatimagene are unproven.
- Financing risk: Company will need additional capital beyond Q1 2028 runway to fund operations and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-386561 |
| Document: d738484d8k.htm | 0001193125-26-386561 |
| Document: 0001193125-26-386561-index-headers.html | 0001193125-26-386561 |
| Document: 0001193125-26-386561-index.html | 0001193125-26-386561 |
| Document: 0001193125-26-386561.txt | 0001193125-26-386561 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.94 (−21.85%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.94 (−23.95%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.94 (−29.92%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.94 (−29.92%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.94 (−34.70%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.94 (−32.71%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.94 (−32.71%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.94 (−21.15%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.94 (−19.23%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.94 (−19.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers